<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178864</url>
  </required_header>
  <id_info>
    <org_study_id>H17-00440</org_study_id>
    <nct_id>NCT03178864</nct_id>
  </id_info>
  <brief_title>Study of Rivaroxaban for CeREbral Venous Thrombosis</brief_title>
  <acronym>SECRET</acronym>
  <official_title>Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of
      symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SECRET is an open-label, randomized, controlled, phase II study that will assess the safety
      of rivaroxaban, a non-vitamin K antagonist oral anticoagulant (NOAC), compared with
      standard-of-care (unfractionated or low-molecular weight heparin with transition to warfarin
      [INR 2.0-3.0], or continued low molecular-weight heparin) for cerebral venous thrombosis.
      Recruitment will occur at 15 high-volume stroke research centres across Canada over 3 years.
      Three hundred and forty-eight adult patients within 14 days of diagnosis of symptomatic
      cerebral venous thrombosis will be randomized to receive rivaroxaban 20 mg daily versus
      standard-of-care (regimen at the discretion of the local investigator in keeping with AHA/ASA
      guidelines). Patients will be followed for 1 year. The feasibility of recruitment will also
      be tested.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of all-cause mortality, symptomatic intracranial bleeding, major extracranial bleeding</measure>
    <time_frame>180 days</time_frame>
    <description>Symptomatic intracranial bleeding is defined as a new symptomatic intracranial hemorrhage OR worsening existing intracranial hemorrhage with a &gt;33% change in hematoma volume, AND either an NIHSS score increase of 4 or more points, or a change in level of consciousness as per NIHSS item 1a, AND the clinical change is thought to be attributable to the hemorrhage.
Major extracranial bleeding is defined as bleeding in a critical area or organ, including intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a drop in hemoglobin by 20 g/L or more, leading to transfusion of 2 or more units of whole blood or red cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>180 days</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial bleeding</measure>
    <time_frame>180 days</time_frame>
    <description>Symptomatic intracranial bleeding is defined as a new symptomatic intracranial hemorrhage OR worsening existing intracranial hemorrhage with a &gt;33% change in hematoma volume, AND either an NIHSS score increase of 4 or more points, or a change in level of consciousness as per NIHSS item 1a, AND the clinical change is thought to be attributable to the hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major extracranial bleeding</measure>
    <time_frame>180 days</time_frame>
    <description>Major extracranial bleeding is defined as bleeding in a critical area or organ, including intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a drop in hemoglobin by 20 g/L or more, leading to transfusion of 2 or more units of whole blood or red cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent venous thromboembolism</measure>
    <time_frame>180 days</time_frame>
    <description>any thrombosis at a new site including cerebral venous thrombosis in a separate localization from index event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding or clinically relevant non-major bleeding</measure>
    <time_frame>180 days</time_frame>
    <description>A clinically relevant minor bleed is an acute or subacute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of: (a) a hospital admission for bleeding, or (b) a physician guided medical or surgical treatment for bleeding, or (c) a change in antithrombotic therapy (including interruption or discontinuation or study drug)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial or complete recanalization</measure>
    <time_frame>180 days</time_frame>
    <description>Partial or complete recanalization between baseline and last study venogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional independence</measure>
    <time_frame>180 days</time_frame>
    <description>modified Rankin Scale 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced functional dependence</measure>
    <time_frame>180 days</time_frame>
    <description>shift of one or more modified Rankin Scale categories to reduced functional dependence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care resource utilization</measure>
    <time_frame>180 days</time_frame>
    <description>Cost in Canadian dollars of number of hospitalizations (length of stay, critical care unit use), emergency room visits, unscheduled outpatient consultations, postacute care (including home care, rehabilitation stays or long-term care)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Health Questionnaire (PHQ)-9 score</measure>
    <time_frame>180 days</time_frame>
    <description>Change in PHQ-9 score between baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQOL 5-Dimensions (EQ-5D) score</measure>
    <time_frame>180 days</time_frame>
    <description>Change in EQ-5D score between baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Assessment score</measure>
    <time_frame>180 days</time_frame>
    <description>Change in fatigue assessment score between baseline and end of study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Cerebral Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban 20 mg daily (15 mg daily in participants with a GFR of &lt;50 mL/min as per the Cockroft-Gault equation)</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.</description>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Heparin, Coumadin, Fragmin, Lovenox, Innohep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 and above.

          -  New diagnosis of symptomatic cerebral venous thrombosis as confirmed on CT venogram or
             MR venogram

          -  Randomization within 14 days of neuroimaging-confirmed diagnosis.

          -  The treating clinician is of the opinion that the patient is appropriate for
             anticoagulation as per standard of care

        Exclusion Criteria:

          -  Patient is anticipated to require invasive procedure (e.g. lumbar puncture,
             thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation

          -  Patient is unable to swallow due to depressed level of consciousness

          -  Impaired renal function (CrCl &lt; 30 mL/min using Cockroft-Gault equation).

          -  Pregnancy; if a woman is of childbearing potential a urine or serum beta human
             chorionic gonadotropin (Î²-hCG) test is positive.

          -  Breastfeeding at the time of randomization.

          -  Bleeding diathesis or other contraindication to anticoagulation.

          -  Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant
             use.

          -  Concomitant use of strong CYP3A4 inducers (eg. ongoing use of dilantin, carbamazepine,
             HIV protease inhibitors, systemic ketoconazole) or CYP3A4 inhibitors (eg. diltiazem,
             efavirenz).

          -  Patient has a severe or fatal comorbid illness that will prevent improvement, or
             cannot complete follow-up due to the same, or cannot complete follow-up due to
             co-morbid non-fatal illness, non-residence in the city, or for any other known reason
             for which follow-up would be impossible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thalia S Field, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thalia S Field, MD FRCPC</last_name>
    <phone>604-875-4554</phone>
    <email>thalia.field@ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karina Villaluna Murray, RN CCRP</last_name>
    <phone>604-875-4554</phone>
    <email>karina@bcstrokecentre.ca</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Thalia Field</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cerebral venous thrombosis</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon completion of the SECRET Trial, a public use database will be prepared by stripping any and all personal identifiers. The public use database, consisting of several data files, should contain: (1) baseline and demographic characteristics; (2) outcomes assessments; (3) CT/MRI data; (4) concomitant medications and procedures; and (5) adverse events. Each data file is made available as a formatted SAS dataset or other electronic format. The data files are distributed along with the data dictionary and a brief instruction (&quot;Readme&quot;) file. These data files will be made available to the public only after all major manuscripts (including secondary analysis papers) of the Trial are accepted for publication in peer-reviewed journals.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

